Urine test could replace malignant melanoma biopsies

Molecules in urine can let doctors track the impact of a melanoma treatment.

Malignant melanoma is notoriously aggressive skin cancer, capable of quickly spreading throughout the body. That means that it must be closely monitored once discovered — if one treatment isn’t working, there’s no time to waste in trying another.

To diagnose and track the progression of malignant melanoma, doctors will surgically remove a bit of a patient’s skin and tissue — a procedure called a “biopsy” — so that they can then analyze the sample in the lab.

This process can be painful, expensive, and time consuming — and new research suggests that a simple urine test might be able to replace it.

This test could be performed using standard laboratory equipment.

Ivana Špaková

During the process of growing and spreading, cancer cells produce waste molecules that eventually leave the body through urine.

These molecules are fluorescent, which means they can be spotted using a simple, inexpensive detection method called “fluorescence spectroscopy.”

Researchers at Pavol Jozef Šafárik University in Slovakia suspected that doctors could monitor a patient’s response to a melanoma treatment by tracking the levels of the molecules in their urine.

If the levels were going down, it would indicate that a treatment was working. Up, and the patient’s cancer was progressing.

To put their theory to the test, the researchers measured the levels of the fluorescent molecules in the urine of malignant melanoma patients and healthy controls for a study now published in the journal Open Chemistry.

As they expected, the levels corresponded with the progression of a patient’s melanoma.

“Our results show that we can successfully use urine, a simply and non-invasively collected biological material, to determine the progression and treatment response of malignant melanoma,” researcher Ivana Špaková said in a news release.

“This method is a user friendly and straightforward technique which could be performed using standard laboratory equipment,” she added.

We’d love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at [email protected].

The placenta may play a role in the genetic risk of schizophrenia
Researchers at Johns Hopkins have found that genes associated with schizophrenia risk may impact the placenta, not just the brain.
Gain-of-function research is more than just tweaking risky viruses
Gain-of-function experiments in the lab can help researchers get ahead of viruses naturally gaining the ability to infect people in the wild.
Chronic pain can be objectively measured using brain signals
Even though pain is universal and we know it happens in the brain, we’ve never before had a way to objectively measure its intensity.
Do we finally know what causes Alzheimer’s?
The first treatments proven to slow cognitive decline in Alzheimer’s are helping settle a decades-long debate about how the disease starts.
This “bridge” between chemo and cancer solves a big problem for treatment
To improve leukemia treatment, Australian researchers have created a bispecific antibody that connects chemo drugs to cancer cells.
Up Next
love hormone
Subscribe to Freethink for more great stories